Barclays PLC Has $285,000 Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Barclays PLC lifted its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAFree Report) by 294.2% in the third quarter, HoldingsChannel reports. The firm owned 27,438 shares of the biotechnology company’s stock after purchasing an additional 20,478 shares during the period. Barclays PLC’s holdings in Enanta Pharmaceuticals were worth $285,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Rhumbline Advisers lifted its stake in Enanta Pharmaceuticals by 4.7% during the second quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock valued at $448,000 after buying an additional 1,548 shares in the last quarter. US Bancorp DE raised its holdings in shares of Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 4,243 shares during the period. American Century Companies Inc. lifted its position in shares of Enanta Pharmaceuticals by 35.4% in the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after acquiring an additional 7,287 shares in the last quarter. Quest Partners LLC boosted its stake in Enanta Pharmaceuticals by 65.0% in the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 7,535 shares during the period. Finally, FMR LLC grew its position in Enanta Pharmaceuticals by 18.9% during the 3rd quarter. FMR LLC now owns 49,301 shares of the biotechnology company’s stock worth $511,000 after purchasing an additional 7,839 shares in the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Wall Street Analyst Weigh In

ENTA has been the subject of a number of research analyst reports. JMP Securities restated a “market outperform” rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. HC Wainwright reduced their price objective on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, December 24th. Finally, Robert W. Baird lowered their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Check Out Our Latest Report on ENTA

Enanta Pharmaceuticals Trading Up 8.2 %

NASDAQ ENTA opened at $5.25 on Tuesday. Enanta Pharmaceuticals, Inc. has a 1-year low of $4.71 and a 1-year high of $17.80. The firm’s fifty day simple moving average is $7.12 and its 200-day simple moving average is $10.65. The company has a market capitalization of $111.27 million, a PE ratio of -0.96 and a beta of 0.56.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Free Report) last issued its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The firm had revenue of $14.60 million during the quarter, compared to analysts’ expectations of $17.99 million. During the same quarter last year, the firm earned ($1.33) EPS. The business’s revenue for the quarter was down 22.8% compared to the same quarter last year. As a group, analysts predict that Enanta Pharmaceuticals, Inc. will post -4.93 EPS for the current year.

Insider Buying and Selling

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 13.64% of the stock is currently owned by corporate insiders.

About Enanta Pharmaceuticals

(Free Report)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

See Also

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAFree Report).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.